European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Novel nanotechnology-enabled system for endovascular in vivo near-infrared fluorescence molecular imaging and endovascular near-infrared targeted photodynamic therapy of atherosclerotic heart disease

Obiettivo

CosmoPHOS-nano is a multidisciplinary, translational and business-oriented project, aiming to accomplish the following objectives:
1) develop the CosmoPHOS system, which is a novel theranostic (diagnostic & therapeutic) nanotechnology-enabled portable combination system enabling endovascular in vivo near-infrared fluorescence molecular imaging, endovascular near-infrared targeted photodynamic therapy, real-time & follow-up therapy monitoring of atherosclerotic coronary artery disease (CAD),
2) nonclinically evaluate this system,
3) clinically validate the system after regulatory approval, &
4) reduce in the long-term CAD deaths and morbidity by up to 40%, resulting in a significant decrease of the European and global healthcare costs for CAD, increasing the income of the European healthcare industry from CAD market which is the global largest. The CosmoPHOS-nano consortium has a five year history of successful collaboration between the industrial and academic partners, and its funding would underpin a team devoted to delivering a novel powerful & affordable healthcare solution against the leading cause of death, without the need for heavy and expensive medical equipment.
The CosmoPHOS system consists of two interacting components:
a) targeted theranostic near-infrared photoactivatable biocompatible nanomedicines, and
b) medical devices.
After systemic administration, the nanomedicines targeted accumulate in coronary atherosclerotic plaques, followed by endocoronary photoactivation and detection by the medical devices, enabling molecular imaging, targeted therapy, real-time & follow-up therapy monitoring of CAD. Preliminary in vitro & in vivo successful experimental results, as well as parts of the CosmoPHOS system are already available from the prior five year collaboration.
The project plan includes: A) nonclinical R&D (30 months); B) nonclinical validation & regulatory approval (18 months); C) first-in-man phase-I clinical trial in 20 CAD patients (12 months).

Campo scientifico

Programma(i)

Argomento(i)

Invito a presentare proposte

FP7-NMP-2012-LARGE-6
Vedi altri progetti per questo bando

Meccanismo di finanziamento

CP-IP - Large-scale integrating project

Coordinatore

ITA-SUOMEN YLIOPISTO
Contributo UE
€ 2 029 689,65
Indirizzo
YLIOPISTONRANTA 8
70211 KUOPIO
Finlandia

Mostra sulla mappa
Regione
Manner-Suomi Pohjois- ja Itä-Suomi Pohjois-Savo
Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Jaana Backman (Ms.)
Collegamenti
Costo totale
Nessun dato

Partecipanti (18)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 2 Agosto 2019

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/310337/it

European Union, 2024